NMT.001

NMT.001 is an antisense oligonucleotide (ASO) therapy developed by Neumirna Therapeutics for the treatment of drug-resistant epilepsy (DRE). It functions as a selective inhibitor of microRNA-134 (miR-134), a non-coding RNA implicated in the regulation of neuronal network excitability and epileptogenesis. Preclinical studies in rodent, canine, and human models have demonstrated that inhibition of miR-134 with NMT.001 leads to disease modification, including reduced seizure frequency, improved survival, and even long-term seizure cessation without tachyphylaxis or significant adverse effects. The mechanism involves modulation of conserved biological pathways linked to neuronal structure and function relevant to epilepsy[1][4][5][7].